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Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of
coronavirus disease 2019 (COVID-19), which has rapidly become epidemic in Italy and other European
countries. The disease spectrum ranges from asymptomatic/mildly symptomatic presentations to acute
respiratory failure. At the present time the absolute number of severe cases requiring ventilator support
is reaching or even surpassing the intensive care unit bed capacity in the most affected regions and
countries.
Objectives: To narratively summarize the available literature on the management of COVID-19 in order to
combine current evidence and frontline opinions and to provide balanced answers to pressing clinical
questions.
Sources: Inductive PubMed search for publications relevant to the topic.
Content: The available literature and the authors' frontline-based opinion are summarized in brief
narrative answers to selected clinical questions, with a conclusive statement provided for each answer.
Implications: Many off-label antiviral and anti-inflammatory drugs are currently being administered to
patients with COVID-19. Physicians must be aware that, as they are not supported by high-level evidence,
these treatments may often be ethically justifiable only in those worsening patients unlikely to improve
only with supportive care, and who cannot be enrolled onto randomized clinical trials. Access to well-
designed randomized controlled trials should be expanded as much as possible because it is the mostses Unit, Ospedale Policlinico
zi, 10-16132, Genoa. Italy.
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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
is the causative agent of coronavirus disease 2019 (COVID-19),
which has rapidly become epidemic in Italy and other European
countries [1e3]. The disease spectrum ranges from asymptomatic/
mildly symptomatic presentations to acute respiratory failure, with
the true proportion of severe cases still remaining partly unclear as
a result of an incomplete denominator and a possible lack of
adjustment for relevant confounding factors [4,5]. Nonetheless, of
particular clinical concern at the present time is not the relative
frequency of severe cases in patients requiring ventilation support,
but rather their absolute number, which is reaching or even sur-
passing the intensive care unit (ICU) bed capacity in the most
affected regions and countries [6].
From this perspective, in addition to the important prevention
and restrictive measures implemented for reducing transmission
[7], it remains crucial to optimize the therapeutic management of
symptomatic patients requiring noninvasive oxygen therapy in
order both to improve the absolute cure rates and to reduce and
prevent the need for ICU admission. However, the lack of high-level
evidence, inherent to the novelty and rapid spread of COVID-19, has
led to the adoption of heterogeneous approaches worldwide, often
without a clear distinction between the relative weight of available
evidence and expert opinion in informing therapeutic choices.
In this narrative review, we sought to summarize the available
evidence on important therapeutic questions we are continuously
facing as clinicians caring for COVID-19 patients in Italy, trying to
find a balance between current evidence, frontline experiences and
expert opinions.
Methods
Members of a panel of 17 experts from the Italian Society of
Anti-infective Therapy (SITA) and the Italian Society of Pulmonol-
ogy (SIP) were selected; they developed a list of 8 practical thera-
peutic questions to be addressed. The members of the panel (which
included infectious diseases specialists and pneumonologists) were
divided into small groups and asked to summarize the available
literature and their frontline-based opinion in brief (500 words
maximum) narrative answers, plus a conclusive statement for each
answer. All the answers and statements were ultimately reviewed
and discussed by the entire panel until a consensus was reached. A
brief summary of questions and conclusive statements is available
in Table 1. Table 2 summarizes available or ongoing randomized
controlled trial (RCT) information for off-label/compassionate-use
drugs mostly used for the treatment of COVID-19 patients. Of
note, we focused on pneumologic and anti-infective/anti-
inflammatory treatments; the discussion of the therapeutic
approach to COVID-19erelated cardiovascular/coagulative disor-
ders is outside the scope of this narrative review.
Question 1. how to use at best oxygen therapy and noninvasive
mechanical ventilation for preventing intubation?
In moderate to severe cases, COVID-19 usually presents as a lung
disease (mostly in the form of bilateral interstitial pneumonia)alancing evidence and frontli
ve Therapy (SITA) and the Italcausing hypoxic respiratory failure and requiring passive oxygen
therapy. The prevalence of hypoxic respiratory failure in patients
with COVID-19 may be as high as 19% [8]. In observational studies
conducted in China, 4% to 13% of COVID-19 patients received
noninvasive positive pressure ventilation, and 2.3% to 12% required
invasive mechanical ventilation [8e10].
In general, oxygen treatment should be provided to patients
with shortness of breath or hypoxaemia, or those in shock, which is
aimed at maintaining an appropriate level of peripheral capillary
oxygen saturation (SpO2), avoiding values of SpO2 lower than 90%
(92e95% in pregnant women). During oxygen supplementation,
SpO2 should not surpass 96% [11].
An alternative to conventional oxygen supplementation is sup-
plementation through high-flow nasal cannula (HFNC). HFNC is an
oxygen supply system that provides a mixture of air and oxygen
with a known concentration. HFNC provides high concentrations of
humidified oxygen and low levels of positive end-expiratory
pressure; it can also facilitate the elimination of carbon dioxide,
thereby potentially reducing the need for intubation compared to
standard oxygen supplementation [12e14]. However, it should also
be considered that there are no standard evidence-based guide-
lines for the use of HFNC and that the experience in patients with
COVID-19 is still limited (and without adjusted comparison to
standard oxygen supplement) to provide universal recommenda-
tions, at least pending further data [9]. Other relevant things to be
considered are: (a) HFNC should be used in settings with rapid
availability of endotracheal intubation in the case of rapid deteri-
oration [15]; and (b) the possible increased risk of contracting the
infection for healthcare personnel as a result of aerosol generation
should be appropriately managed (HFNC should be used in
negative-pressure rooms) [16]. These two considerations also apply
to continuous positive airway pressure (CPAP) with helmet (the
most frequent system of noninvasive mechanical ventilation used
in real life), which can be considered if the patient does not respond
to standard or HFNC oxygen supplementation (i.e. if the ratio of
arterial oxygen partial pressure to fractional inspired oxygen (PaO2/
FiO2) has a decreasing trend) and there is no urgent indication for
endotracheal intubation. As for HFNC, also in the case of CPAP with
helmet, close monitoring and short interval assessment for wors-
ening of respiratory failure are mandatory. In addition, it should be
necessarily noted that although CPAP with helmet has become an
established procedure for primary hypoxemic lung failure in the
last few years, some experts do not support its use for COVID-19
[15], arguing that success rates in critically ill COVID-19 patients
may be limited and there could be a risk of delayed intubation
unfavourably influencing the outcome. However, considering the
atypical physiopathology of acute lung injury in patients with
COVID-19 [17], gentle ventilation with a positive end expiratory
pressure (PEEP) not higher than 10 to 12 cm of water may represent
a reasonable approach for avoiding excessive damage during CPAP
with helmet and possibly also the need for intubation. Large
studies, possibly RCT, are urgently needed to definitely clarify the
precise role of CPAP with helmet in patients with COVID-19. Finally,
borrowing from what is already known and used in intensive care,
pronation, although certainly more difficult to implement during
noninvasive than invasive mechanical ventilation, may allowne experience in the early phases of the COVID-19 pandemic: current
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Table 1
Summary of questions and statements
Question Statement
Question 1. How to use at best oxygen therapy and
noninvasive mechanical ventilation for preventing
intubation?
Supplementary oxygen should be administered to patients with hypoxic respiratory failure for avoiding
values of SpO2 lower than 90% and it should be aimed at reaching values not higher than 96%. Although
still without firm evidence, we currently support the use of CPAP helmet (with gentle ventilation and a
PEEP of no more than 10e12 cm of water) if the patient does not respond to standard/HFNC oxygen
supplementation and there is no urgent indication for endotracheal intubation (expert opinion).
However, no clear indications/criteria can be provided pending further experience. Finally, it should be
kept in mind that patients with COVID-19 can get worse in a few hours, so they should be carefully
monitored for worsening respiratory function for rapidly prompting tracheal intubation andmechanical
ventilation.
Question 2. Should antiviral agents be administered? At the present time, evidence from the first published RCT does not support off-label treatment with
LPV/RTV in COVID-19 patients. This result should also discourage the use of other protease inhibitors
(e.g. darunavir), at least until results of dedicated RCT are available. Although promising in preclinical
studies, remdesivir should be currently provided to COVID-19 patients only within RCT (preferentially)
or compassionate-use/expanded-access programmes, owing to its investigational nature. Pending high-
level supporting evidence, favipiravir and umifenovir should not be provided an outside RCT, at least in
those countries where they are not approved for other indications. Oseltamivir or zanamivir should be
provided only in the presence of suspected/proven concomitant influenza.
Question 3. Should chloroquine/hydroxychloroquine be
administered?
Pending results of RCT, the use of hydroxychloroquine may be considered for treating worsening
patients with COVID-19 only if no important drug interactions can be anticipated and with close
monitoring of hepatic, renal function and QT prolongation. This is based on its activity in vitro against
SARS-CoV-2 (althoughweak) and on the availability of low-level clinical evidence of anticipation of virus
clearance from a small controlled, nonrandomized study. However, it should also be kept in mind that
the study was highly susceptible to bias and there are still no data regarding hard clinical endpoints such
as crude mortality. For these reasons, hydroxychloroquine should be preferentially administered within
the framework of investigational studies. When this is unfeasible, off-label use may be considered
according to local protocols and consent procedures. In view of the absence of evidence, we are currently
unable to support the use of hydroxychloroquine in asymptomatic or mildly symptomatic
nonhospitalized patients outside investigational studies. The same applies to prophylactic use.
Question 4. Should antibiotics be administered? In our opinion, it might be prudent to consider empiric antibiotic treatment in critically ill patients with
pneumonia due to COVID-19 in whom bacterial infection cannot be excluded. This suggestion is based
on the fact that bacterial coinfection (a) is common in patients with viral pneumonia and (b) can be
associated with a substantial risk of delaying appropriate treatment, thereby potentially increasing
mortality. Because of the limited available data on both the microbiologic epidemiology (and the
prevalence of antimicrobial resistance) of bacterial superinfections in COVID-19 patients, it is difficult to
provide specific pathogen-oriented recommendations. Therefore, pending further studies, we suggest to
empirically treat COVID-19 patients according to their clinical syndrome (e.g. community-acquired
pneumonia, hospital-acquired pneumonia), choosing the best antimicrobial agent or agents on the basis
of local guidelines and local antibiotic susceptibility patterns, with early de-escalation or
discontinuation according to microbiology results, whenever available.
Question 5. Should steroids be administered? So far, no definitive efficacy or effectiveness data are available on the benefit of corticosteroid
administration in patients with SARS-CoV-2 infection. As the WHO underlines, there is an important
need for efficacy data from RCT for supporting corticosteroid therapy in patients with SARS-Cov-2.
However, considering that overwhelming inflammation and cytokine-related lung injury might be
responsible for rapidly progressive pneumonia and clinical deterioration in COVID-19 patients, we
suggest (expert opinion only) to consider administration of corticosteroids in critically ill COVID-19
patients with ARDS or with worsening of non-ARDS respiratory failure in the absence of bacterial/fungal
superinfections (independent of ICU admission). Yet in the absence of convincing evidence, the
following cannot currently be supported: (1) steroid administration stratified according to inflammatory
markers; and (b) steroid administration in nonecritically ill COVID-19 patients.
Question 6. Should other immunosuppressive and/or
immunomodulatory therapies be administered?
Owing to the lack of high-level evidence, administration of tocilizumab to patients with COVID-19
should preferentially occur within the framework of RCT. Off-label use according to local protocols and
consent procedures may be considered only in those COVID-19 patients excluded from RCT (or
hospitalized where RCT are not available or still to be implemented) and who are worsening while
receiving standard supportive care (in the absence of concomitant/superimposed infections). In our
opinion, this could be a reasonable off-label use of tocilizumab in these early phases of the COVID-19
pandemic, although patients and physicians should be aware that currently there is only a nonepeer-
reviewed, noncomparative, observational experience (very low evidence from an unreviewed cases
series) and that it only supports a potential favourable effect on inflammatory signs and symptoms,
while there is no information on any possible effect on survival. In the absence of clinical studies, we
suggest to preferentially administer also other immunosuppressive and/or immunomodulatory
therapies (e.g. anakinra, Janus kinase family enzyme inhibitors) within RCT. This also applies to
modifications of the immune response through high-dose intravenous immunoglobulins or plasma
from convalescent patients, which, although promising in small case series, both deserve dedicated RCT
investigation to clearly understand their role in impacting COVID-19 outcomes and their tolerability.
Question 7. What is the optimal timing of treatment
initiation?
Supportive therapy (symptomatic therapy, rehydration and oxygen supplementation, if necessary),
should be initiated as soon as the patient manifests respiratory or systemic symptoms, including severe
asthenia, high fever, persistent cough and/or clinical or radiologic signs of lung involvement. Pending
further evidence, in our opinion, antiviral treatments should not be provided to patients with SARS-CoV-
2 infection outside RCT or compassionate-use programmes (with the exception of early oseltamivir
initiation in patients with suspected concomitant influenza). Corticosteroids should be provided early in
well-defined categories of patients (patients with ARDS or with worsening of non-ARDS respiratory
failure in the absence of bacterial/fungal superinfections), while their role in other COVID-19 patients
still remains uncertain. Although based on low-level evidence and pending RCT results, in our opinion,
(continued on next page)
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Table 1 (continued )
Question Statement
early hydroxychloroquine administration may be considered in COVID-19 patients manifesting
moderate to severe symptoms, whereas further data are needed to better delineate the true balance
between possible favourable effects and toxicity of hydroxychloroquine in mildly symptomatic and
asymptomatic patients.
Question 8. What is the optimal treatment duration? Chloroquine/hydroxychloroquine treatment should be continued for at least 5 days, and possibly up to
20 days, according to some expert opinions, although it should be noted that data regarding the relative
safety of different lengths of administration in COVID-19 patients are currently unavailable. Early
discontinuation should be considered in the presence of adverse effects (e.g. QT prolongation or hepatic/
renal toxicity). If the administration of remdesivir is approved within compassionate-use/expanded-
access programmes, treatment duration should follow compassionate or expanded access protocols (e.g.
up to 10 days according to the most recent compassionate protocol at the time of this review). If
corticosteroids are provided, we suggest a total treatment duration of 7e10 days, with progressive dose
reduction. If the patient's condition deteriorates with worsening lung physiology after withdrawal of
steroid treatment in the absence of bacterial or fungal superinfection, a second course of corticosteroid
treatment may be considered, followed by slow tapering after improvement.
ARDS, acute respiratory distress syndrome; COVID-19, coronavirus disease 2019; CPAP, continuous positive airway pressure; HFNC, high-flow nasal cannula; ICU, intensive
care unit; LPV/RTV, lopinavir/ritonavir; PEEP, positive end expiratory pressure; RCT, randomized controlled trial; SARS-CoV-2, severe acute respiratory syndrome coronavirus
2; WHO, World Health Organization.
M. Bassetti et al. / Clinical Microbiology and Infection xxx (xxxx) xxx4improved gas exchange and decreased respiratory distress, and
may also promote lung recruitment [18].
Question 1 statement
Supplementary oxygen should be administered to patients with
hypoxic respiratory failure for avoiding values of SpO2 lower than
90%, and it should be aimed at reaching values not higher than 96%.
Although still without firm evidence, we currently support the use
of CPAP helmet (with gentle ventilation and a PEEP of no more than
10e12 cm of water) if the patient does not respond to standard/
HFNC oxygen supplementation and there is no urgent indication for
endotracheal intubation (expert opinion). However, no clear in-
dications/criteria can be provided pending further experience.
Finally, it should be kept in mind that patients with COVID-19 can
get worse in a few hours, so they should be closely monitored for
worsening respiratory function so that tracheal intubation and
mechanical ventilation can be quickly performed if needed.
Question 2. should antiviral agents be administered?
Several antiviral agents have demonstrated in vitro activity
against SARS-CoV-2 or other coronaviruses, but currently there are
no approved antiviral agents for coronavirus-related diseases, and
there are still no favourable efficacy results from RCT available at
the present time. Lopinavir is a protease inhibitor used for the
treatment of HIV patients, administered in combination with rito-
navir to improve its serum half-life. On the basis of its activity
against SARS-CoV-1 and/or Middle East respiratory syndrome
(MERS)-CoV observed in in vitro and animal studies [19e21], lopi-
navir/ritonavir (LPV/RTV) was compared to supportive care alone
for the treatment of COVID-19 patients in an open-label RCT in
China [22]. The primary time-to-event endpoint was clinical
improvement from randomization (defined as a composite of
discharge from the hospital or improvement of two points on a
seven-category ordinal scale, ranging from no need of hospitali-
zation to death). Overall, 199 patients were enrolled (99 and 100 in
the LPV/RTV and supportive care arms, respectively). No differ-
ences were observed in the intent-to-treat population with regard
to clinical improvement (hazard ratio 1.24 with standard of care as
reference, 95% confidence interval (CI) 0.90 to 1.72). In addition, no
associations were observed with regard to 28-day mortality,
although a smaller number of deaths were registered in the LPV/
RTV arm (19.2% vs. 25.0% in investigational and comparator arms,
respectively; percentage difference 5.8%, 95% CI 17.3 to 5.7).Please cite this article as: Bassetti M et al., Balancing evidence and frontli
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judgement on the possible efficacy of LPV/RTV (e.g. some major
limitations are the open-label nature of the trial and the fact that
LPV/RTV was initiated late with respect to the onset of symptoms;
see question 7), especially in the case of early therapy initiation, the
results of this RCT provide evidence currently discouraging the use
of LPV/RTV (or of other protease inhibitors such as darunavir) in
COVID-19 patients (also considering the potential side effects;
Table 3), unless favourable results from other ongoing RCT in spe-
cific subgroups of patients are available (Table 2). Furthermore,
harmful drug interactions of antivirals with other drugs (such as
hydroxychloroquine) cannot be excluded a priori because there are
currently no large clinical data about the use of these combinations.
Remdesivir is an investigational nucleotide analogue undergo-
ing clinical development for Ebola and showing in vitro activity
against coronaviruses (SARS-CoV-2, SARS-CoV-1 and MERS-CoV)
and favourable effects in animal MERS models [23e26]. Following
these promising preclinical findings, RCT in COVID-19 patients have
been initiated (Table 2). However, pending their results, and
considering the investigational nature of the drug, access to
remdesivir outside RCT is currently provided only within strictly
regulated and limited compassionate-use/expanded-access
frameworks.
Oseltamivir and zanamivir are neuraminidase inhibitors used
for treating influenzawhich are also being tested in RCT for treating
COVID-19 patients (Table 2). However, no apparent activity of
oseltamivir and zanamivir has previously been observed against
SARS-CoV-1 in vitro [27], and the fact that up to 76% of the first
critically ill patients with COVID-19 received oseltamivir may also
be related to the suspicion of infection (or coinfection) with influ-
enza [28]. Overall, this information is currently insufficient for
supporting the use of these agents in COVID-19 patients unless in
the presence of suspected/proven concomitant influenza.
Other antiviral agents currently being investigated in RCT for the
treatment of COVID-19 patients are favipiravir, an RNA-dependent
RNA polymerase inhibitor with anti-influenza activity, and umife-
novir, and anti-influenza membrane fusion inhibitor [29]. Even
though these two agents attracted important media attention in
the last few months, and even though there were some favourable
preliminary results, especially for favipiravir, released as preprints,
we advocate caution in using these agents outside investigational
studies until completion of the standard peer-review processes of
the first released trials. For example, in a recent RCT comparing 120
COVID-19 patients treated with favipiravir versus 120 COVID-19ne experience in the early phases of the COVID-19 pandemic: current
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Table 2
Available and ongoing RCT on anti-infective and anti-inflammatory drugs most provided as off-label/compassionate treatments in the first phase of the COVID-19 pandemic
Drug Class/mechanism Published RCT Ongoing RCT for treatment/prevention of COVID-19
(recruiting or not yet recruiting) registered at
ClinicalTrials.gov
Lopinavir/ritonavir Lopinavir is an HIV type 1
protease inhibitor. Ritonavir is a
CYP3A4 inhibitor that boosts
lopinavir concentrations
 Open-label RCT comparing lopinavir/
ritonavir (99 patients) vs. standard of
care (100) in patients with COVID-19
in China. Lopinavir/ritonavir was
administered at the dosage of 400/
100 mg for 14 days. The primary
time-to-event endpoint was clinical
improvement from randomization. In
the primary study population (ITT),
no statistically significant differences
were observed with regard to the
primary endpoint of clinical
improvement (HR 1.24 with standard
of care as reference, 95% CI 0.90 to
1.72) and the secondary endpoint of
28-day mortality (19.2% vs. 25.0% in
investigational and comparator arms,
respectively; percentage
difference 5.8%, 95% CI 17.3 to
5.7). In the mITT population, lopina-
vir/ritonavir led to a median time to
clinical improvement that was
shorter by 1 day than that observed
with standard care. Median time be-
tween symptoms onset and
randomization was 13 days (IQR 11
e16) [22]
 Comparison of lopinavir/ritonavir vs.
hydroxychloroquine in patients with mild COVID-19.
Open-label RCT (NCT04307693, recruiting). Primary
endpoint: virus load at day 3, 5, 7, 10, 14 and 18.
 Comparison of ASC09/ritonavir vs. lopinavir/ritonavir in
patients with confirmed COVID-19 pneumoniae. Open-
label RCT (NCT04261907, not yet recruiting). Primary
endpoint: adverse outcome at day 14 (composite of
SpO2  93% without oxygen supplementation, PaO2/
FiO2  300 mm Hg or respiratory rate  30 breaths per
minute).
 Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir
plus umifenovir in patients with COVID-19. Open-label
RCT (NCT04252885, recruiting). Primary endpoint: rate of
virus inhibition at day 0, 2, 4, 7, 10, 14 and 21.
 Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir
plus ribavirin plus interferon beta 1b in patients with
COVID-19. Open-label RCT (NCT04276688, recruiting).
Primary endpoint: time to negative nasopharyngeal swab
RT-PCR (follow-up 30 days).
 Comparison of only supportive treatment vs. lopinavir/
ritonavir vs. oseltamivir vs. umifenovir in patients with
confirmed COVID-19 pneumonia. Open-label RCT
(NCT04255017, recruiting). Primary endpoints: (a) rate of
disease remission (mild disease: fever, cough and other
symptoms relieved with improved lung CT; severe dis-
ease: fever, cough and other symptoms relieved with
improved lung CT, SpO2 > 93% or PaO2/FiO2 > 300 mmHg);
(b) time to lung recovery.
 Comparison of chemoprophylaxis with lopinavir/
ritonavir vs. placebo in healthcare workers exposed to
COVID-19. Double-blind RCT (NCT04328285, not yet
recruiting). Primary endpoint: occurrence of a symp-
tomatic or asymptomatic COVID-19 (follow-up
2.5 months).
 Comparison of carrimycin vs. lopinavir/ritonavir or
umifenovir or chloroquine in patients with COVID-19
pneumonia. Open-label RCT (NCT04286503, not yet
recruiting). Primary endpoints: (a) fever to normal time
(follow-up 30 days); (b) pulmonary inflammation reso-
lution time (follow-up 30 days); (c) negative conversion
of throat swab RT-PCR at EOT.
 Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir
plus xiyanping (injectable component derived from a
plant used in traditional Chinese medicine) in patients
with COVID-19. Open-label RCT (NCT04295551, not yet
recruiting). Primary endpoint: clinical recovery time
(follow-up 28 days).
 Comparison of lopinavir/ritonavir plus inhaled interferon
alfa vs. lopinavir/ritonavir plus inhaled interferon alfa
plus xiyanping injection in patients with COVID-19.
Open-label RCT (NCT04275388, not yet recruiting). Pri-
mary endpoint: clinical recovery time (follow-up
14 days).
 Comparison of lopinavir/ritonavir plus inhaled interferon
alfa vs. lopinavir/ritonavir plus inhaled interferon alfa
plus traditional Chinese medicines in patients with
COVID-19. Open-label RCT (NCT04251871, recruiting).
Primary endpoint: time to complete remission of symp-
toms (follow-up 28 days).
 Comparison of lopinavir/ritonavir plus
hydroxychloroquine vs. lopinavir/ritonavir plus
hydroxychloroquine plus levamisole pill plus budesonide
plus formoterol inhaler in patients with nonsevere
COVID-19 pneumonia. Partly blinded RCT (NCT04331470,
not yet recruiting). Primary endpoint: (a) clear CT scan at
3e7 days; (b) negative RT-PCR at 3e7 days.
 Comparison of lopinavir/ritonavir vs.
hydroxychloroquine vs. losartan vs. placebos in patients
with COVID-19. Double-blind, adaptive RCT
(NCT04328012, not yet recruiting). Primary endpoint:
(continued on next page)
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Table 2 (continued )
Drug Class/mechanism Published RCT Ongoing RCT for treatment/prevention of COVID-19
(recruiting or not yet recruiting) registered at
ClinicalTrials.gov
NIAID COVID-19 ordinal severity scale (follow-up
60 days).
 Comparison of lopinavir/ritonavir vs.
hydroxychloroquine vs. lopinavir/ritonavir plus
interferon beta 1a vs. remdesivir vs. standard of care in
patients with COVID-19. Double-blind, adaptive RCT
(NCT04315948, recruiting). Primary endpoint: severity
rating on a 7-point ordinal scale at day 15.
 Comparison of lopinavir/ritonavir or umifenovir or
chloroquine or hydroxychloroquine or oseltamivir (with
or without azithromycin) vs. natural honey plus
lopinavir/ritonavir or umifenovir or chloroquine or
hydroxychloroquine or oseltamivir (with or without
azithromycin) in patients with COVID-19. Single-blind
RCT (NCT04323345, not yet recruiting). Primary end-
points: (a) positive to negative swabs at day 14; (b) fever
to normal temperature in days (follow-up 14 days); (c)
resolution of lung inflammation in CT or X-ray (follow-up
30 days).
 Comparison of colchicine (with or without lopinavir/
ritonavir) vs. local standard of care in patients with
moderate to severe COVID-19. Open-label RCT
(NCT04328480, not yet recruiting). Primary endpoint: all-
cause mortality (follow-up 30 days).
 Comparison of oseltamivir plus chloroquine vs.
oseltamivir plus lopinavir/ritonavir in patients with
mild COVID-19 and of lopinavir/ritonavir plus oseltamivir
vs. darunavir/ritonavir plus oseltamivir vs. favipiravir
plus lopinavir/ritonavir vs. darunavir/ritonavir plus osel-
tamivir plus chloroquine vs. darunavir/ritonavir plus
favipiravir plus oseltamivir in patients with moderate to
severe COVID-19. Open-label RCT (NCT04303299, not yet
recruiting). Primary endpoint: SARS-CoV-2 eradication
time (follow-up 24 weeks).
Remdesivir Adenosine analogue. It binds to
RNA-dependent RNA
polymerase and acts as an RNA-
chain terminator
 Not available  Comparison of remdesivir vs. placebo in patients with
severe COVID-19. Double-blind RCT (NCT04257656,
recruiting). Primary endpoint: clinical status, assessed by
an ordinal scale at days 7, 14, 21 and 28.
 Comparison of remdesivir vs. placebo in patients with
mild to moderate COVID-19. Double-blind RCT
(NCT04252664, recruiting). Primary endpoint: time to
clinical recovery in hours (follow-up 28 days).
 Comparison of remdesivir vs. local standard of care in
patients with severe COVID-19. Open-label RCT
(NCT04252664, recruiting). Primary endpoint: composite
of fever normalization and oxygen saturation normali-
zation (follow-up 14 days).
 Comparison of remdesivir vs. local standard of care in
patients with moderate COVID-19. Open-label RCT
(NCT04292730, recruiting). Primary endpoint: dis-
charged status at day 14.
 Comparison of remdesivir vs. placebo in patients with
COVID-19. Double-blind RCT (NCT04280705, recruiting).
Primary endpoint: severity rating on a 8-point ordinal
scale at day 15.
 Comparison of remdesivir vs. hydroxychloroquine vs.
remdesivir plus hydroxychloroquine in patients with
COVID-19. Open-label adaptive RCT (NCT04321616, not
yet recruiting). Primary endpoint: all-cause in-hospital
mortality (follow-up 3 weeks).
 Comparison of lopinavir/ritonavir vs.
hydroxychloroquine vs. lopinavir/ritonavir plus
interferon beta 1a vs. remdesivir vs. standard of care in
patients with COVID-19. Double-blind, adaptive RCT
(NCT04315948, recruiting). Primary endpoint: severity
rating on a 7-point ordinal scale at day 15.
Darunavir/cobicistat Darunavir is an HIV type 1
protease inhibitor. Cobicistat is
a CYP3A4 inhibitor that boosts
darunavir concentrations
 Not available  Comparison of darunavir/cobicistat vs. standard of care in
patients with COVID-19 pneumonia. Open-label RCT
(NCT04252274, recruiting). Primary endpoint: virologic
clearance rate of throat swabs, sputum or lower respira-
tory tract secretions at day 7.
Favipiravir Anti-influenza RNA-dependent
RNA polymerase inhibitor
 In a recent RCT published on a
preprint server and comparing 120
 Comparison of favipiravir vs. tocilizumab vs. favipiravir
plus tocilizumab in patients with COVID-19. Open-label
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Table 2 (continued )
Drug Class/mechanism Published RCT Ongoing RCT for treatment/prevention of COVID-19
(recruiting or not yet recruiting) registered at
ClinicalTrials.gov
COVID-19 patients treated with favi-
piravir vs. 120 COVID-19 patients
receiving umifenovir, higher rates of
clinical recovery were observed in
patients receiving favipiravir. The
manuscript is publicly available but
still to be peer reviewed [30]
RCT (NCT04310228, recruiting). Primary endpoint: clin-
ical cure (follow-up 3 months).
 Comparison of oseltamivir plus chloroquine vs.
oseltamivir plus lopinavir/ritonavir in patients with
mild COVID-19 and of lopinavir/ritonavir plus oseltamivir
vs. darunavir/ritonavir plus oseltamivir vs. favipiravir
plus lopinavir/ritonavir vs. darunavir/ritonavir plus osel-
tamivir plus chloroquine vs. darunavir/ritonavir plus
favipiravir plus oseltamivir in patients with moderate to
severe COVID-19. Open-label RCT (NCT04303299, not yet
recruiting). Primary endpoint: SARS-CoV-2 eradication
time (follow-up 24 weeks).
 Comparison of hydroxychloroquine plus darunavir/
cobicistat vs. standard of care in patients with COVID-
19. Open-label RCT (NCT04304053, recruiting). Primary
endpoint: incidence of secondary cases among contacts of
a case and contacts of contacts (follow-up 14 days).
 Comparison of chloroquine plus favipiravir vs. favipiravir
vs. placebo in patients with COVID-19. Double-blind RCT
(NCT04319900, recruiting). Primary endpoints: (a) time
to improvement/recovery and frequency of improve-
ment/recovery (follow-up 10 days); (b) time to negative
swab/sputum RT-PCR (follow-up 10 days).
 Comparison of favipiravir vs. standard of care in patients
with COVID-19. Open-label RCT (NCT04333589, not yet
recruiting). Primary endpoint: viral nucleic acid test
negative conversion rate in nasopharyngeal swabs
(follow-up 5 months).
 Comparison of oseltamivir plus chloroquine vs.
oseltamivir plus lopinavir/ritonavir in patients with
mild COVID-19 and of lopinavir/ritonavir plus oseltamivir
vs. darunavir/ritonavir plus oseltamivir vs. favipiravir
plus lopinavir/ritonavir vs. darunavir/ritonavir plus osel-
tamivir plus chloroquine vs. darunavir/ritonavir plus
favipiravir plus oseltamivir in patients with moderate to
severe COVID-19. Open-label RCT (NCT04303299, not yet
recruiting). Primary endpoint: SARS-CoV-2 eradication
time (follow-up 24 weeks).
Umifenovir Anti-influenza membrane
fusion inhibitor
 In a recent RCT published on a
preprint server and comparing 120
COVID-19 patients treated with favi-
piravir vs. 120 COVID-19 patients
receiving umifenovir, higher rates of
clinical recovery were observed in
patients receiving favipiravir. The
manuscript is publicly available but
still to be peer reviewed [30]
 Comparison of umifenovir vs. standard of care in patients
with COVID-19 pneumonia. Open-label RCT
(NCT04260594, not yet recruiting). Primary endpoint:




are the following: increase in
the endosomal Ph necessary for
the virus/host cell fusion;
interference with the
glycosylation of cell receptors;
immunomodulatory activity
 Not available  Comparison of different hydroxychloroquine dosages vs.
placebo in three cohorts (outpatients, inpatients,
healthcare workers a risk). Double-blind RCT for out-
patients and healthcare workers and open-label RCT for
inpatients (NCT04329923, not yet recruiting). Primary
endpoints: (a) release from quarantine (outpatients,
follow-up 14 days); (b) discharge (inpatients, follow-up
14 days); (c) development of COVID-19 (healthcare
workers, follow-up 2 months).
 Comparison of hydroxychloroquine vs. ascorbic acid in
contacts of COVID-19 patients. Double-blind RCT
(NCT04328961, not yet recruiting). Primary endpoint:
laboratory-confirmed COVID-19 (follow-up 14 days).
 Comparison of tocilizumab plus hydroxychloroquine plus
azithromycin vs. tocilizumab plus hydroxychloroquine in
patients with COVID-19. Open-label RCT (NCT04332094,
not yet recruiting). Primary endpoints: (a) in-hospital
mortality (follow-up 2 weeks); (b) need for mechanical
ventilation in the ICU (follow-up 2 weeks). Comparison
of ciclesonide plus hydroxychloroquine vs. ciclesonide in
patients with COVID-19. Open-label RCT (NCT04330586,
not yet recruiting). Primary endpoint: SARS-CoV-2 erad-
ication (based on virus load) at day 14.
 Comparison of hydroxychloroquine vs. placebo in
patients with COVID-19 and under biological treatment
(continued on next page)
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Table 2 (continued )
Drug Class/mechanism Published RCT Ongoing RCT for treatment/prevention of COVID-19
(recruiting or not yet recruiting) registered at
ClinicalTrials.gov
and/or JAK inhibitors. Double-blind RCT (NCT04330495,
not yet recruiting). Primary endpoints: (a) incidence rate
of COVID-19 (follow-up 27 weeks); (b) prevalence of
COVID-19 (follow-up 27 weeks); (c) case fatality rate
(follow-up 27 weeks); (d) ICU admission rate (follow-up
27 weeks).
 Comparison of hydroxychloroquine vs. placebo for the
prevention of COVID-19 in healthcare workers at risk.
Double-blind RCT (NCT04328467, not yet recruiting).
Primary endpoint: prevalence of COVID-19 (follow-up
12 weeks).
 Comparison of chemoprophylaxis with lopinavir/
ritonavir vs. placebo in healthcare workers exposed to
COVID-19. Double-blind RCT (NCT04328285, not yet
recruiting). Primary endpoint: Occurrence of a symp-
tomatic or asymptomatic SARS-CoV-2 infection (follow-
up 2.5 months).
 Comparison of hydroxychloroquine vs. placebo in
symptomatic COVID-19 patients or exposed healthcare
workers/households. Double-blind RCT (NCT04308668,
recruiting). Primary endpoints: (a) incidence of symp-
tomatic COVID-19 among asymptomatic participants; (b)
severity rating on a 3-point ordinal scale at day 14.
 Comparison of remdesivir vs. hydroxychloroquine vs.
remdesivir plus hydroxychloroquine in patients with
COVID-19. Open-label adaptive RCT (NCT04321616, not
yet recruiting). Primary endpoint: all-cause in-hospital
mortality (follow-up 3 weeks).
 Comparison of lopinavir/ritonavir vs.
hydroxychloroquine vs. losartan vs. placebos in patients
with COVID-19. Double-blind, adaptive RCT
(NCT04328012, not yet recruiting). Primary endpoint:
NIAID COVID-19 Ordinal Severity Scale (follow-up
60 days).
 Comparison of convalescent plasma plus
hydroxychloroquine plus azithromycin vs.
hydroxychloroquine plus azithromycin in hospitalized
patients with COVID-19. Open-label RCT (NCT04332835,
not yet recruiting). Primary endpoints: (a) change in virus
load at days 0, 4, 7, 14 and 28; (b) change in IgM COVID-
19 titers at days 0, 4, 7, 14 and 28; (c) change in IgG at
days 0, 4, 7, 14 and 28.
 Comparison of lopinavir/ritonavir vs.
hydroxychloroquine vs. lopinavir/ritonavir plus
interferon beta-1a vs. remdesivir vs. standard of care in
patients with COVID-19. Double-blind, adaptive RCT
(NCT04315948, recruiting). Primary endpoint: severity
rating on a 7-point ordinal scale at day 15.
Methylprednisolone A subgroup of patients with
severe COVID-19might develop
a cytokine storm syndrome
which causes rapidly
progressive pneumonia, ARDS
and clinical deterioration and
corticosteroids administration
may halt the dysregulated
cytokine release
 Not available  Comparison of methylprednisolone vs. standard of care in
patients with severe COVID-19. Open-label RCT
(NCT04244591, recruiting). Primary endpoint: lower
Murray lung injury score at days 7 and 14.
 Comparison of methylprednisolone vs. standard of care in
patients with COVID-19. Open-label RCT (NCT04273321,
recruiting). Primary endpoint: treatment failure (follow-
up 14 days).
 Comparison of inhaled alpha interferon plus
methylprednisolone plus umifenovir vs. thalidomide
plus inhaled alpha interferon plus methylprednisolone
plus umifenovir in patients with severe COVID-19. Dou-
ble-blind RCT (NCT04273581, not yet recruiting). Primary
endpoint: time to clinical improvement (follow-up
28 days).
 Comparison of different dosages of methylprednisolone
in patients with COVID-19. Open-label RCT
(NCT04263402, recruiting). Primary endpoints: (a) dis-
ease readmission at day 7; (b) critical stage at day 7.
 Comparison of siltuximab (antieIL-6 monoclonal
antibody) vs. methylprednisolone in patients with
COVID-19. Open-label RCT (NCT04329650, not yet
recruiting). Primary endpoint: ICU admission (follow-up
29 days)
Tocilizumab  Not available
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Drug Class/mechanism Published RCT Ongoing RCT for treatment/prevention of COVID-19





soluble IL-6 receptors. IL-6, is
one of the main drivers of
immunologic response and
symptoms in patients with
dysregulated cytokine release
that has been observed in
severe COVID-19
 Comparison of tocilizumab vs. standard of care in patients
with COVID-19. Open-label RCT (NCT04331808, not yet
recruiting). Primary endpoint: WHO progression scale at
day 7 and 14 (severity rating on a 10-point ordinal scale).
 Comparison of favipiravir vs. tocilizumab vs. favipiravir
plus tocilizumab in patients with COVID-19. Open-label
RCT (NCT04310228, recruiting). Primary endpoint: clin-
ical cure (follow-up 3 months).
 Comparison of tocilizumab vs. placebo in hospitalized
patients with COVID-19. Double-blind RCT
(NCT04320615, not yet recruiting). Primary endpoint:
severity rating on a 7-point ordinal scale at day 28.
 Comparison of tocilizumab plus hydroxychloroquine plus
azithromycin vs. tocilizumab plus hydroxychloroquine in
patients with COVID-19. Open-label RCT (NCT04332094,
not yet recruiting). Primary endpoints: (a) in-hospital
mortality (follow-up 2 weeks); (b) need for mechanical
ventilation in the ICU (follow-up 2 weeks).
 Comparison of chloroquine analog (GNS651) vs.
tocilizumab vs. nivolumab vs. standard of care in
patients with advanced or metastatic cancer and COVID-
19. Open-label RCT (NCT04333914, not yet recruiting).
Primary endpoint: 28-day survival.
 Comparison of tocilizumab intravenously vs. tocilizumab
subcutaneously vs. sarilumab (anti-interleukin 6 receptor
a monoclonal antibody) subcutaneously vs. standard of
care in patients with COVID-19. Open-label RCT
(NCT04322773, not yet recruiting). Primary endpoint:
time to independence from supplementary oxygen ther-
apy (follow-up 28 days).
 Comparison of tocilizumab vs. anakinra (recombinant IL-
1 receptor antagonist) vs. siltuximab vs. anakinra plus
siltuximab vs. anakinra plus tocilizumab vs. standard of
care in patients with COVID-19. Open-label RCT
(NCT04330638, not yet recruiting). Primary endpoint:
time to clinical improvement (follow-up 15 days).
 Comparison of carrimycin vs. lopinavir/ritonavir or
umifenovir or chloroquine in patients with COVID-19
pneumonia. Open-label RCT (NCT04286503, not yet
recruiting). Primary endpoints: (a) fever to normal time
(follow-up 30 days); (b) pulmonary inflammation reso-
lution time (follow-up 30 days); (c) negative conversion
of throat swab RT-PCR at EOT.
Anakinra Antagonist of IL-1 receptor. IL-1
is one of the main drivers of
immunologic response and
symptoms in patients with
cytokine-release syndrome.
 Not available  Comparison of anakinra vs. emapalumab (antieinterferon
g monoclonal antibody) vs. standard of care in patients
with COVID-19. Open-label RCT (NCT04324021, not yet
recruiting). Primary endpoint: treatment success at day
15.
 Comparison of tocilizumab vs. anakinra (recombinant IL-
1 receptor antagonist) vs. siltuximab vs. anakinra plus
siltuximab vs. anakinra plus tocilizumab vs. standard of
care in patients with COVID-19. Open-label RCT
(NCT04330638, not yet recruiting). Primary endpoint:
time to clinical improvement (follow-up 15 days).
Off-label drugs mostly provided in Italy during the first phase of the COVID-19 pandemic according to the authors' direct experience. Of note, there are also registered RCT for
other drugs to be investigated in patients with COVID-19 (e.g. the Janus kinase family inhibitors ruxolitinib, baricitinib and tofacitinib).
ARDS¼ acute respiratory distress syndrome; CI, confidence interval; COVID-19, coronavirus disease 2019; CT, computed tomography; EOT, end of treatment; HR, hazard ratio;
Ig, immunoglobulin; IL-1, interleukin 1; IQR, interquartile range; ITT, intent to treat; mITT, modified intent to treat; PaO2/FiO2, of arterial oxygen partial pressure to fractional
inspired oxygen; RCT, randomized controlled trial; RT-PCR, real-time PCR; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health Organization.
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observed in patients receiving favipiravir, but it is of note that the
all-cause mortality was 0 in the entire study population, making it
uncertain whether, if confirmed, these favourable results may be
extrapolated to relevant survival endpoints in critically ill COVID-19
patients [30]. Finally, antiviral activity against SARS-CoV-2 in vitro
has been recently reported for ivermectin, but clinical data are still
lacking [31].Please cite this article as: Bassetti M et al., Balancing evidence and frontlin
position of the Italian Society of Anti-infective Therapy (SITA) and the Ital
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At the present time, evidence from the first published RCT does
not support off-label treatment with LPV/RTV in COVID-19 patients.
This result should also discourage the use of other protease in-
hibitors (e.g. darunavir), at least until results of dedicated RCT are
available. Although promising in preclinical studies, remdesivir
should be currently provided for treating COVID-19 patients only
within RCT (preferentially) or compassionate-use/expanded-access
programmes, owing to its investigational nature. Pending high-e experience in the early phases of the COVID-19 pandemic: current
ian Society of Pulmonology (SIP), Clinical Microbiology and Infection,
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provided outside RCT, at least in those countries where they are not
approved for other indications. Oseltamivir or zanamivir should be
provided only in the presence of suspected/proven concomitant
influenza.Question 3. should chloroquine/hydroxychloroquine be
administered?
The rationale of using chloroquine for treating COVID-19 pa-
tients is based on two potential and nonemutually exclusive
mechanisms: antiviral activity and immunomodulatory effects.
With regard to antiviral activity, chloroquine has been shown to
inhibit various viruses in cell cultures, including SARS-CoV-1 and
SARS-CoV-2, possibly via pH-dependent inhibition of
viruseendosome fusion and/or posttranslational modifications of
CoV proteins, although other mechanisms may also contribute
[32e35]. With regard to the immunomodulatory effects, the
attenuated production of tumor necrosis factor alpha, interleukin
(IL)-6 and interferons that follows the administration of chloro-
quine might help counteract an exaggerated proinflammatory
response, which is thought to contribute to the organ damage
observed in SARS-CoV-2einfected patients [36,37]. However, some
authors have pointed out that an unfavourable immunomodulatory
effect cannot be excluded, based on a reduced T helper 2 differ-
entiation [38]. In our opinion, hydroxychloroquine should be
preferred over chloroquine because of its less toxic profile (reduced
ocular toxicity and fewer drug interactions) and its more potent
in vitro activity against SARS-CoV-2 [39].
Recently, Cortegiani et al. [40] reviewed the available informa-
tion on ongoing case series, comparative observational studies and
RCT evaluating the use of chloroquine or hydroxychloroquine in
patients with COVID-19 and registered in Chinese or US registries.
They found 23 studies, all being conducted in China. However, in
the fewweeks after the paper was made available online (10 March
2020), the number of registered studies being conducted in coun-
tries other than China has multiplied (Table 2). In particular, results
of registered RCT are necessary to guide (or discourage) the use of
chloroquine/hydroxychloroquine in two different settings: pro-
phylaxis of exposed individuals and treatment of proven cases,
stratified for the severity of clinical presentation/progression.
In the meantime, a small controlled nonrandomized study of
COVID-19 patients treated with hydroxychloroquine has been
recently published [41]. In this study, Gautret et al. enrolled 26
COVID-19 patients to receive 200 mg of hydroxychloroquine every
8 hours for 10 days, whereas a total of 16 patients who denied
consent as well as untreated patients from another centre were
included as controls. Of note, six patients treated with hydroxy-
chloroquine also received azithromycin. The primary endpoint was
virologic clearance (based on results of real-time PCR on naso-
pharyngeal specimens) at day 6 after inclusion. At day 6, 70% (14/
20) of hydroxychloroquine-treated patients were virologically
cured versus 12.5% (2/16) in the control group (p 0.001), although it
cannot be excluded that selection bias and baseline virus load
played a role in influencing results, thereby biasing results towards
observing a favourable effect of hydroxychloroquine administration
[42]. Furthermore, the opposite results (apparent absence of
reduction of virus clearance) were recently described by another
French group (albeit in a tiny sample size of 11 patients receiving
hydroxychloroquine plus azithromycin) [43]. Uncertainty also sur-
rounds the more marked positive effect observed in patients
receiving azithromycin in addition to hydroxychloroquine in the
study by Gautret et al., especially because of the very small number
of patients in the combined treatment subgroup and the possiblePlease cite this article as: Bassetti M et al., Balancing evidence and frontli
position of the Italian Society of Anti-infective Therapy (SITA) and the Ital
https://doi.org/10.1016/j.cmi.2020.04.031increased risk of QT prolongation by combining the two drugs
(Table 3).
Question 3 statement
Pending results of RCT, the use of hydroxychloroquine may be
considered for treating worsening patients with COVID-19 only if
no important drug interactions can be anticipated and with close
monitoring of hepatic function, renal function and QT
prolongation. This is based on its activity in vitro against SARS-
CoV-2 (although weak) and on the availability of low-level clin-
ical evidence of anticipation of virus clearance from a small
controlled nonrandomized study. However, it should also be kept in
mind that the study was highly susceptible to bias and there are
still no data regarding hard clinical endpoints such as crude mor-
tality. For these reasons, hydroxychloroquine should be preferen-
tially administeredwithin the framework of investigational studies.
When this is unfeasible, off-label use may be considered according
to local protocols and consent procedures. In view of the absence of
evidence, we are currently unable to support the use of hydroxy-
chloroquine in asymptomatic or mildly symptomatic nonhospital-
ized patients outside investigational studies. The same applies to
prophylactic use.
Question 4. should antibiotics be administered?
Bacterial infections can present simultaneously with COVID-19
or occur later during the course of the disease, worsening clinical
conditions of patients who were recovering from primary viral
pneumonia. Information regarding the prevalence of bacterial co-
infection or superinfection is scant [28,44,45]. According to the
available reports, prevalence of bacterial infections in patients with
COVID-19 ranges between 1% and 10% [28,44,46]. In these reports,
bacterial infections were due to Gram-negative bacteria including
Enterobacterales and nonfermenting rods [28,44]. It is of note that
up to 98% of COVID-19 patients in available experiences received
intravenous broad-spectrum empirical antibiotics [28,44,45,47],
probably reflecting the frequent inability to exclude the presence of
bacterial coinfection at the onset of severe clinical presentations of
COVID-19. This could have possibly lowered the overall prevalence
of bacterial superinfections.
Extrapolating data from experiences on bacterial superinfection
in pneumonia due to other viruses in a retrospective case series of
critically ill patients with MERS in Saudi Arabia, bacterial infection
was registered in 18% of patients [48]. With similar prevalence,
bacterial pneumonia occurred in about 20% of patients hospitalized
for primary influenza virus infection [49,50]. In these studies,
mortality related to influenza was mostly due to secondary bacte-
rial pneumonia [49,50]. Common bacteria implicated were Staph-
ylococcus aureus, including methicillin-resistant strains [51],
Streptococcus pneumoniae, Haemophilus influenzae and group A
streptococci [49,52,53].
There are currently no large data regarding any possible
favourable effects in COVID-19 patients related to possible anti-
inflammatory or antiviral effect of azithromycin. Furthermore, the
small experiences of the administration of azithromycin in COVID-
19 patients have provided conflicting results.
Question 4 statement
In our opinion, it might be prudent to consider empiric anti-
biotic treatment in critically ill patients with pneumonia due to
COVID-19 in whom bacterial infection cannot be excluded. This
suggestion is based on the facts that bacterial coinfection is com-
mon in patients with viral pneumonia and that it can be associated
with a substantial risk of delaying appropriate treatment, thereby
potentially increasing mortality. Because of the limited availablene experience in the early phases of the COVID-19 pandemic: current
ian Society of Pulmonology (SIP), Clinical Microbiology and Infection,
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of antimicrobial resistance) of bacterial superinfections in COVID-
19 patients, it is difficult to provide specific pathogen-oriented
recommendations. Therefore, pending further studies, we suggest
to empirically treat COVID-19 patients according to their clinical
syndrome (e.g. community-acquired pneumonia, hospital-acquired
pneumonia), choosing the best antimicrobial agent or agents on the
basis of local guidelines and local antibiotic susceptibility patterns,
with early de-escalation or discontinuation according to microbi-
ology results, whenever available.
Question 5. should steroids be administered?
So far, no RCT has been performed on corticosteroids adminis-
tration in patients with COVID-19, and there are controversial
opinions regarding the extrapolation of inference from previous
studies in SARS-CoV-1 and MERS-CoV patients [15,54,55].
In an observational study conducted in 84 COVID-19 patients
with acute respiratory distress syndrome (ARDS) in China, admin-
istration of methylprednisolone was associated with reduced pro-
gression to death (hazard ratio 0.38, 95% confidence interval
0.20e0.72, p 0.003), although the unadjusted analysis and the
relatively small sample size preclude firm generalization and call
for further investigation [47]. Indirect data on the possible efficacy
(RCT) or effectiveness (observational comparative studies) of
corticosteroid therapy come from studies performed in patients
with MERS-CoV, SARS-CoV-1 or other viral infections.
With regard to patients with mild clinical presentation, a RCT
including 16 not critically ill patients with SARS-CoV-1 did not
report a beneficial effect of hydrocortisone administration. Of note,
higher viraemia was observed in the second and third weeks after
infection in the hydrocortisone group compared to the control
group [56]. Moreover, as reported in a systematic review and meta-
analysis of observational studies on corticosteroids provided to
patients with SARS-CoV-1, only four studies provided conclusive
data, reporting no survival benefit and possible harms including
avascular necrosis, psychosis, diabetes and delayed virus clearance
[57].
In critically ill patients, corticosteroids may be provided to
decrease the inflammationecoagulationefibroproliferation
observed during acute respiratory distress syndrome (ARDS)
[58e61]. A meta-analysis on corticosteroid use in ARDS including
eight controlled studies reported a significant reduction in markers
of systemic inflammation, pulmonary and extrapulmonary organ
dysfunction scores, duration of mechanical ventilation and ICU
length of stay [62]. A recent multicentre RCT included 277 patients
with ARDS to assess the effects of dexamethasone treatment. Pa-
tients in the study arm received dexamethasone 20 mg once daily
from day 1 to day 5, which was reduced to 10 mg once daily from
day 6 to day 10. This study reported a significant reduction in
duration of mechanical ventilation in the dexamethasone group
than in the control group (between-group difference 4.8 days,
p < 0.0001) and a significant reduction in mortality at 60 days
(between-group difference 15.3%, p 0.0047). The proportion of
adverse events did not differ significantly between the dexameth-
asone group and the control group [63].
Data on the use of corticosteroids in critically ill patients with
SARS-CoV-1 and MERS-CoV infection are available, albeit with
conflicting results. In a retrospective observational study of 152
SARS-CoV-1einfected, critically ill patients, corticosteroid therapy
was found to reduce mortality and shorten the length of hospital
stay (odds ratio 0.08, 95% confidence intervals 0.01e0.97, p 0.046).
The study did not report increased secondary infections or other
complications with corticosteroid administration [64]. Conversely,
in a retrospective observational study on 309 critically ill patientsPlease cite this article as: Bassetti M et al., Balancing evidence and frontlin
position of the Italian Society of Anti-infective Therapy (SITA) and the Ital
https://doi.org/10.1016/j.cmi.2020.04.031with MERS-CoV, the administration of a median hydrocortisone
equivalent dose of 300 mg per day was not associated with a dif-
ference in 90-day mortality. In addition, corticosteroid adminis-
tration was associated with delayed clearance of MERS-CoV RNA
from the patients' respiratory tract [65].
With regard to other viral infections, it is worth noting that a
recent meta-analysis on patients with influenza pneumonia
(including ten observational studies with a total of 6548 included
patients) reported increased mortality (risk ratio: 1.75, 95% CI
1.3e2.4; p 0.0002), increased length of ICU stay (mean difference:
2.1, 95% CI 1.2e3.1; p < 0.0001) and increased rate of secondary
bacterial or fungal infection (risk ratio: 2.0, 95% CI 1.0e3.8; p 0.04)
in patients who received corticosteroids [66].
Question 5 statement
So far, no definitive efficacy or effectiveness data are available on
the benefit of corticosteroid administration in patients with SARS-
CoV-2 infection. As the World Health Organization underlines,
there is an important need for efficacy data from RCT for supporting
corticosteroids therapy in patients with SARS-CoV-2. However,
considering that overwhelming inflammation and cytokine-related
lung injury might be responsible for the rapidly progressive
pneumonia and clinical deterioration in COVID-19 patients
[44,58,67], we suggest (expert opinion only) to consider adminis-
tration of corticosteroids in critically ill COVID-19 patients with
ARDS or with worsening of non-ARDS respiratory failure in the
absence of bacterial/fungal superinfections (independent of ICU
admission). However, in the absence of convincing evidence, the
following cannot currently be supported: steroid administration
stratified according to inflammatory markers and steroid admin-
istration in nonecritically ill COVID-19 patients.
Question 6. should other immunosuppressive and/or
immunomodulatory therapies be administered?
According to some recent evidence, some patients with COVID-
19 may develop secondary haemophagocytic lymphohistiocytosis,
an underrecognized hyperinflammatory syndrome characterized
by a fulminant and fatal hypercytokinaemia, with development of
ARDS and multiorgan failure [46,47,67]. Consequently, immuno-
suppressive and/or immunomodulatory therapies have been pro-
posed to contrast COVID-19eassociated hyperinflammation.
Tocilizumab is a recombinant humanized monoclonal antibody
inhibiting membrane-bound and soluble IL-6 receptors [68] and is
currently approved for the treatment of patients with rheumatoid
arthritis, giant-cell arteritis, juvenile idiopathic arthritis and pa-
tients with chimeric antigen receptor T-celleinduced severe or life-
threatening cytokine release syndrome [68,69]. In this regard,
tocilizumab may help mitigate the cytokine release syndrome by
decreasing cytokine concentrations and acute-phase reactant pro-
duction [70]. In a recent preprint paper, Xu et al. [71] reported their
experience of treating 21 COVID-19 patients with tocilizumab. In
their still-to-be-peer-reviewed case series, the following were
observed after tocilizumab administration: (a) reduction in body
temperature (21/21, 100%); (b) improved blood oxygenation (15/21,
71.4%); (c) normalization of lymphocyte count (10/17, 58.8%); (d)
normalization of C-reactive protein (16/19, 82.4%); and (c) resolu-
tion of abnormalities on computed tomography (19/21, 90.5%).
Interestingly, no adverse reactions were observed after tocilizumab
administration, but long-term follow-up was not available. Tocili-
zumab has been deemed by Chinese National Health Commission
to be a possible treatment option for patients with severe COVID-19
with elevated IL-6 [72]. The recommended dose is 4 to 8 mg/kg or
400 mg standard dose provided intravenously once, with the op-
tion to repeat a dose after 8 to 12 hours (not to exceed a total dose ofe experience in the early phases of the COVID-19 pandemic: current
ian Society of Pulmonology (SIP), Clinical Microbiology and Infection,
Table 3
Known adverse events of marketed anti-infective and anti-inflammatory drugs mostly provided as off-label treatments in the first phase of the COVID-19 pandemic
Drug Adverse events
Lopinavir/ritonavir  Hypercholesterolaemia and increased serum triglycerides (3e39%)
 Increased g-glutamyl transferase (10e29%)
 Diarrhoea (7e28%; greater with once-daily dosing)
 Increased serum ALT (grade 3/4: 1e11%)
 Nausea (5e16%)
 Upper respiratory tract infection (14%)
 Abdominal pain (1e11%)
 Vomiting (2e7%)
 Fatigue (8%)
 Increased serum amylase and/or lipase (3e8%)
 Headache (2e6%)
 Skin rash (5%)
 Neutropenia (grade 3/4: 1e5%)
 Anxiety (4%)
 Insomnia (4%)
Chloroquine/hydroxychloroquine  Retinopathy (4% of treated patients)a
 Other adverse effects with unknown frequency included Stevens-Johnson syndrome, abdominal pain, diarrhoea,
nausea, vomiting, agranulocytosis, leukopenia, thrombocytopenia, abnormal hepatic function tests, acute hepatic
ailure, myopathy, bronchospasm
 Risk of prolonged QT interval, further increased when administered with fluoroquinolones or azithromycin
Tocilizumab  Increased serum ALT (36%) and AST (22%)
 Increased LDL cholesterol (9e10%)
 Injection site reaction (4e10%)





 Abdominal pain (2%)
 Oral mucosa or gastric ulcers (2%)
 Infections due to Pneumocystis, Mycobacterium tuberculosis and varicella zoster have been reported after
tocilizumab, but their prevalence has not been clearly established
Anakinra  Injection site reactionb (24e71%)
 Antibody development (up to 50% of the patients but no correlation of antibody development and adverse effects)
 Headache and vomiting (12e14%)
 Arthralgia (10e12%)
 Fever (10e12%)
 Haematologic disorder including eosinophilia, leukopenia and change in platelet count (2e9%)
 Nausea and diarrhoea (7e8%)
 Serious infectionc (2e3%)
Off-label drugs mostly provided in Italy during the first phase of the COVID-19 pandemic according to the authors' direct experience.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; COVID-19, coronavirus disease 2019; LDL, low-density lipoprotein.
a Serum concentration dependent adverse effect; early changes are generally reversible but may progress despite discontinuation if advanced.
b Injection site reactions were considered serious in 2e3% of cases.
c Serious infections included cellulitis, pneumonia, and bone and joint infections.
M. Bassetti et al. / Clinical Microbiology and Infection xxx (xxxx) xxx12800 mg). However, it should be noted that the optimal time for
administering tocilizumab has not yet been fully elucidated; nor is
there a clear IL-6 threshold associated with progression to severe
disease. At the time of writing, there are at least eight ongoing RCT
evaluating the efficacy and safety of tocilizumab in COVID-19 pa-
tients (Table 2).
Other immune-modulatory drugs including anakinra (inter-
leukin 1 receptor antagonist) or Janus kinase family enzyme in-
hibitors have been proposed for the management of SARS-CoV-
2einfected patients. Notably, there is currently no supporting
clinical evidence, and RCT are ongoing (Table 2) [67,73].
Finally, modifications of the immune response through
administration of high-dose intravenous immunoglobulin or
convalescent plasma have also been proposed or used in small
case series, and they merit further investigation in dedicated RCT
[74e78].Question 6 statement
Owing to the lack of high-level evidence, administration of
tocilizumab in patients with COVID-19 should preferentially occur
within the framework of RCT. Off-label use according to localPlease cite this article as: Bassetti M et al., Balancing evidence and frontli
position of the Italian Society of Anti-infective Therapy (SITA) and the Ital
https://doi.org/10.1016/j.cmi.2020.04.031protocols and consent procedures may be considered only in those
COVID-19 patients excluded from RCT (or hospitalized where RCT
are not available or still to be implemented) and who are wors-
ening while receiving standard supportive care (in the absence of
concomitant/superimposed infections). In our opinion, this could
be a reasonable off-label use of tocilizumab in these early phases
of the COVID-19 pandemic, although patients and physicians
should be fully aware that currently there is only a nonepeer-
reviewed, noncomparative, observational experience (very low
evidence from an unreviewed cases series), and that it only sup-
ports a potential favourable effect on inflammatory signs and
symptoms, while there is no information on any possible effect on
survival.
In the absence of clinical studies, we suggest that also other
immunosuppressive and/or immunomodulatory therapies (e.g.
anakinra, Janus kinase family enzyme inhibitors) should be
preferentially administered within RCT. This also applies to
modifications of the immune response through high-dose
intravenous immunoglobulins or plasma from convalescent
patients, which, although promising in very small case series,
both deserve dedicated RCT investigation to clearly understandne experience in the early phases of the COVID-19 pandemic: current
ian Society of Pulmonology (SIP), Clinical Microbiology and Infection,
M. Bassetti et al. / Clinical Microbiology and Infection xxx (xxxx) xxx 13their tolerability as well as the role they play in affecting COVID-
19 outcomes.Question 7. what is the optimal timing of treatment initiation?
Most clinical data on the timing of antiviral therapy initiation
are derived from studies on viruses other than SARS-CoV-2, and it
remains unclear whether these data can be extrapolated to SARS-
CoV-2. Previous studies in SARS-CoV-1 and influenza showed a
possible favourable impact on mortality of early initiation of anti-
viral treatment after symptoms onset [79e82]. With regard to
SARS-CoV-2, although the results of the previously cited RCT
comparing LPV/RTV versus standard of care eventually does not
support the use of LPV/RTV in patients with COVID-19, it is also of
note that the median time between symptom onset and random-
ization was 13 days (interquartile range, 11e16 days), so in most
cases, the drug was initiated late during the course of the disease
[22]. Consequently, we cannot exclude the possibility that an earlier
initiation of LPV/RTV may be associated with improved prognosis.
In this regard, we think the results of this RCT may be hypothesis
generating andmay help guide the design of further RCT evaluating
the efficacy of LPV/RTV (and/or other antivirals) in an earlier phase
of the disease. However, until such RCT will be available, we think
the currently available clinical evidence is insufficient to support
the use of LPV/RTV and/or other antivirals for treating COVID-19
outside the framework of RCT or compassionate-use programmes.
The optimal time of chloroquine/hydroxychloroquine and cor-
ticosteroids initiation still remains unknown. Although based on
low-level evidence, the positive effect of virus clearance observed
by Gautret et al. [41] was observed in a mixed group of non-ICU
patients with upper respiratory tract symptoms, non-ICU patients
with lower respiratory tract symptoms and asymptomatic subjects,
which overall may support a positive effect of early hydroxy-
chloroquine initiation in non-ICU settings (although information on
the exact time of treatment initiation with respect to symptoms
onset was not provided). With regard to steroid treatment, there is
currently no evidence of a positive impact of early initiation in
nonecritically ill, non-ARDS patients. Although lack of evidence is
not a synonym of lack of effect, in our opinion, steroid treatment,
considering also its potential detrimental effects, should currently
be limited to ARDS patients or non-ARDS patients with worsening
conditions (see question 5).Question 7 statement
Supportive therapy (symptomatic therapy, rehydration and ox-
ygen supplementation, if necessary) should be provided as soon as
the patient presents with respiratory or systemic symptoms
including severe asthenia, high fever, persistent cough and/or
clinical or radiologic signs of lung involvement. Pending further
evidence, in our opinion, antiviral treatments should not be initi-
ated in patients with SARS-CoV-2 infection outside RCT or
compassionate-use programmes (with the exception of early
oseltamivir initiation in patients with suspected concomitant
influenza). Corticosteroids should be initiated early in well-defined
categories of patients (patients with ARDS or with worsening of
non-ARDS respiratory failure in the absence of bacterial/fungal
superinfections), while their role in other COVID-19 patients still
remains uncertain. Although based on low-level evidence and
pending RCT results, in our opinion, early hydroxychloroquine
administration may be considered in COVID-19 patients who have
moderate to severe symptoms, whereas further data are needed to
better delineate the true balance between possible favourable ef-
fects and toxicity of hydroxychloroquine in mildly symptomatic
and asymptomatic patients.Please cite this article as: Bassetti M et al., Balancing evidence and frontlin
position of the Italian Society of Anti-infective Therapy (SITA) and the Ital
https://doi.org/10.1016/j.cmi.2020.04.031Question 8. what is the optimal treatment duration?
In the absence of proven effective treatment, treatment duration
also remains unclear; it is currently based on expert opinion which
is based on treatment durations in other approved indications for
the drugs provided and aimed at a balance between potential ac-
tivity and risk of undesired side effects. Nonetheless, suggested
durations varymarkedly. For example, awide range of chloroquine/
hydroxychloroquine treatment durations (from 5 to 20 days) have
been recommended/provided in different centres/studies, making
it impossible to provide an univocal recommendation in the
absence of direct comparisons of different lengths of treatment
with regard to relevant clinical endpoints (e.g. mortality, ICU
admission) and safety [33,40,41,83e85]. There is no standard ste-
roid treatment duration, with different consensus/study groups
suggesting steroid administration for no longer than 7 to 10 days
[54,85].
Question 8 statement
Chloroquine/hydroxychloroquine treatment should be
continued for at least 5 days and possibly prolonged up to 20 days
according to some expert opinions, although it should be noted that
data regarding the relative safety of different lengths of adminis-
tration in COVID-19 patients are currently unavailable. Early
discontinuation should be considered in the presence of adverse
effects (e.g. QT prolongation or hepatic/renal toxicity; Table 3). If
the administration of remdesivir is approved within
compassionate-use/expanded-access programmes, treatment
duration should follow compassionate or expanded access pro-
tocols (e.g. up to 10 days according to the most recent compas-
sionate protocol at the time of this review). If corticosteroids are
administered, we suggest a total treatment duration of 7 to 10 days,
with progressive dose reduction. If the patient deteriorates with
worsening lung physiology after removal of steroid treatment in
the absence of bacterial or fungal superinfection, a second course of
corticosteroid treatment may be considered, followed by slow
tapering after improvement.
Future perspectives
In these first phases of the COVID-19 pandemic, where there are
no clearly supported and approved treatments, there are two
apparently mutually exclusive forces driving therapeutic choices
supported only by preclinical and/or low-level clinical evidence:
the willingness to administer potentially active therapies to COVID-
19 patients; and the willingness not to harm by administering
potentially inactive therapies that may unfavourably influence the
outcome because of either expected or unexpected toxicity. Finding
the right balance between these two forces is certainly not simple,
but it remains more necessary than ever if we want to rapidly find
effective and safe treatment. For this reason, RCT should always be
the first option to be proposed to patients because RCT are the only
way to provide high-level efficacy and safety information for
optimizing the treatment of future patients. However, even when
rapidly implemented during evolving pandemics, RCT are usually
not immediately available (e.g. even if accelerated, local approval
still and correctly requires time to guarantee ethical standards), and
also many patients are usually excluded from RCT because of strict
selection criteria [86,87]. For some of these patients, off-label uses
(for drugs approved for other indications) and compassionate-use/
expanded-access programmes (for investigational drugs) may
represent an ethically justifiable option in the case of worsening
conditions and unlikely survival with only supportive care.
Against this background, the role of the attending physician is
crucial, by favouring and not discouraging RCT participation (ine experience in the early phases of the COVID-19 pandemic: current
ian Society of Pulmonology (SIP), Clinical Microbiology and Infection,
M. Bassetti et al. / Clinical Microbiology and Infection xxx (xxxx) xxx14favour of off-label administration) whenever the former is possible.
Otherwise, scientific data will still be produced, but most infor-
mation will be burdened by only partially adjustable selection
biases and confounding factors, with consequent risks of incon-
clusive results and low-level supporting evidence for the various
treatment options. If participation in RCT is maximized, high-level
evidence will be available for guiding treatment, with lower-level
evidence from off-label uses still remaining useful for hypothesis-
generating purposes in order to better design further RCT (and
not for directly guiding treatment choices). Notably, this is what, in
our opinion, happened with LPV/RTV: (a) preclinical data sup-
ported activity against coronaviruses; (b) patients were enrolled
onto RCT whenever possible, and otherwise they were offered off-
label administration when not spontaneously improving; (c)
because many patients were rapidly enrolled onto the first RCT,
evidence rapidly become available that in our opinion discouraged
a universal off-label provision of LPV/RTV in COVID-19 patients.Conclusions
Many off-label antiviral and anti-inflammatory drugs are being
administered in this first phase of the COVID-19 pandemic. While
we do not discourage their use, physicians must be aware that
because of the lack of high-level evidence, they may be ethically
justifiable only in those worsening patients unlikely to improve
with only supportive care and who cannot be enrolled onto RCT.
Implementation of well-designed RCT should be expanded as much
as possible, as RCTs are themost secureway to change for the better
our approach to COVID-19 patients, including our frontline
opinions.Transparency Declaration
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